Aligos Therapeutics, Inc. (ALGS)

Market Cap	147.87M
Revenue (ttm)	6.00M
Net Income (ttm)	-76.95M
Shares Out	3.71M
EPS (ttm)	-12.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	468,705
Open	36.78
Previous Close	38.35
Day's Range	36.37 - 41.64
52-Week Range	6.76 - 41.64
Beta	2.73
Analysts	Strong Buy
Price Target	75.00 (+88.25%)
Earnings Date	Nov 6, 2024

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I cli...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: ALGS
• Website: https://www.aligos.com

Financial Performance

In 2023, Aligos Therapeutics's revenue was $15.53 million, an increase of 11.66% compared to the previous year's $13.91 million. Losses were -$87.68 million, -8.71% less than in 2022.

Analyst Forecast

According to one analyst, the rating for ALGS stock is "Strong Buy" and the 12-month stock price forecast is $75.0.

Price Target

$75.0

(88.25% upside)

Analyst Consensus: Strong Buy